
Cancer Research p. 3001 - 3012 (2017)
Update date:2022-07-29
Topics:
Li, Rui
Ding, Chunyong
Zhang, Jun
Xie, Maohua
Park, Dongkyoo
Ding, Ye
Chen, Guo
Zhang, Guojing
Gilbert-Ross, Melissa
Zhou, Wei
Marcus, Adam I.
Sun, Shi-Yong
Chen, Zhuo G.
Sica, Gabriel L.
Ramalingam, Suresh S.
Magis, Andrew T.
Fu, Haian
Khuri, Fadlo R.
Curran, Walter J.
Owonikoko, Taofeek K.
Shin, Dong M.
Zhou, Jia
Deng, Xingming
A rationale exists for pharmacologic manipulation of the serine (S)184 phosphorylation site of the proapoptotic Bcl2 family member Bax as an anticancer strategy. Here, we report the refinement of the Bax agonist SMBA1 to generate CYD-2-11, which has characteristics of a suitable clinical lead compound. CYD-2-11 targeted the structural pocket proximal to S184 in the C-terminal region of Bax, directly activating its proapoptotic activity by inducing a conformational change enabling formation of Bax homooligomers in mitochondrial membranes. In murine models of small-cell and non-small cell lung cancers, including patient-derived xenograft and the genetically engineered mutant KRAS-driven lung cancer models, CYD-2-11 suppressed malignant growth without evident significant toxicity to normal tissues. In lung cancer patients treated with mTOR inhibitor RAD001, we observed enhanced S184 Bax phosphorylation in lung cancer cells and tissues that inactivates the propaoptotic function of Bax, contributing to rapalog resistance. Combined treatment of CYD-2-11 and RAD001 in murine lung cancer models displayed strong synergistic activity and overcame rapalog resistance in vitro and in vivo. Taken together, our findings provide preclinical evidence for a pharmacologic combination of Bax activation and mTOR inhibition as a rational strategy to improve lung cancer treatment.
JIANGXI AIFEIMU TECHNOLOGY CO.,LTD
Contact:+86-570-6040289
Address:FINECHEMICAL PARK,ZIBU TOWN,WANNIAN COUNTY,JIANGXI PROV.,CHINA,ZIP
Tianjin Bright Future Technology Co., Ltd
Contact:0086-22-58016666
Address:NO.136 DongTeng Lake Street Tianjin Economic and Technology Development Area,Tainjin,China
Shanghai Sunway Pharmaceutical Technology Co.,Ltd.
Contact:+86-21-5161 3915
Address:Shanghai YangPu
Shanghai Forever Synthesis Co.,Ltd.
Contact:021-61124658
Address:Zhoukang Road,Pudong New District,Shanghai,China
Shanghai Mio Chemical Co., Ltd
Contact:0086 21- 64401188-622
Address:16 Floor NO.2 Jiefang Building, No. 4855 Dushi Road, 201100 Shanghai, P.R.China
Doi:10.1021/ol400280b
(2013)Doi:10.1002/chir.22101
(2012)Doi:10.1021/acs.orglett.0c03521
(2020)Doi:10.1021/jo00043a025
(1992)Doi:10.1016/j.tetlet.2013.01.041
(2013)Doi:10.1021/ol702892e
(2008)